SavedAdd your journal

Journals / Turkish journal of vascular surgery / 2022 / Cilt: 31 - Sayı: 1

Endovascular treatment versus femoropopliteal bypass surgery for TASC II type C lesions of the superficial femoral artery

Onur SAYDAM
Deniz ŞEREFLİ
Mehmet ATAY
Ayşen Yaprak ENGİN
Pages
25–32
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In TASC II type C patients, ET is a safe therapeutic option with lower in-hospital stay and treatment expenses and similar primary and secondary patency rates to FPB.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, we aimed to compare the outcomes of endovascular treatment (ET) and femoropopliteal artery bypass (FPB) in patients with Trans-Atlantic Inter-Society Consensus (TASC) II type C femoropopliteal lesions.
📊
Key Findings & Data:Patients and methods: A total of 149 patients with symptomatic TASC II type C femoropopliteal lesions who underwent invasive treatment between January 2012 and January 2017 were retrospectively analyzed.
💡
Conclusion & Impact:Conclusion: In TASC II type C patients, ET is a safe therapeutic option with lower in-hospital stay and treatment expenses and similar primary and secondary patency rates to FPB.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: In this study, we aimed to compare the outcomes of endovascular treatment (ET) and femoropopliteal artery bypass (FPB) in patients with Trans-Atlantic Inter-Society Consensus (TASC) II type C femoropopliteal lesions. Patients and methods: A total of 149 patients with symptomatic TASC II type C femoropopliteal lesions who underwent invasive treatment between January 2012 and January 2017 were retrospectively analyzed. The patients were divided into two groups as the ET group (n=46; 34 males, 12 females; mean age: 64.3±10.3 years) and the FPB group (n=103; 82 males, 21 females; mean age: 62.9±8.2 years). Primary and secondary patency rates at 6, 12, and 24 months were evaluated. Results: The primary success rates for ET and FPB were 100%. Primary patency at 6, 12, and 24 months were 93.5%, 89.0%, 69.5%, respectively for ET and 86.4%, 81.5%, 72.8%, respectively for FPB (p>0.05). Secondary patency rates at 6, 12, and 24 months were 97.8%, 93.5%, %84.8, respectively for ET and 96.1%, 90.3%, 79.6%, respectively for FPB group (p=0.41). The length of hospital stay was significantly longer in the FPB group (p<0.001). The cost of treatment was significantly higher in the FBP group (p=0.02). Conclusion: In TASC II type C patients, ET is a safe therapeutic option with lower in-hospital stay and treatment expenses and similar primary and secondary patency rates to FPB.

🔖

Cite This Article

SAYDAM, O., ŞEREFLİ, D., ATAY, M., ENGİN, A. Y. (2022). Endovascular treatment versus femoropopliteal bypass surgery for TASC II type C lesions of the superficial femoral artery. Turkish journal of vascular surgery, Cilt: 31 - Sayı: 1, 25–32. https://ajindex.com/articles/417480

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100:1043-9
  2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;45 Suppl S:S5-67
  3. Abu Dabrh AM, Steffen MW, Asi N, Undavalli C, Wang Z, Elamin MB, et al. Bypass surgery versus endovascular interventions in severe or critical limb ischemia. J Vasc Surg 2016;63:244-53.e11
  4. Wiseman JT, Guzman AM, Fernandes-Taylor S, Engelbert TL, Saunders RS, Kent KC. General and vascular surgery readmissions: A systematic review. J Am Coll Surg 2014;219:552-69.e2
  5. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: The European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763-816
  6. Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: Consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol 2015;65:931-41
  7. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group, et al. Inter- society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33 Suppl 1:S1-75
  8. Scali ST, Rzucidlo EM, Bjerke AA, Stone DH, Walsh DB, Goodney PP, et al. Long-term results of open and endovascular revascularization of superficial femoral artery occlusive disease. J Vasc Surg 2011;54:714-21
  9. AbuRahma AF, Robinson PA, Holt SM. Prospective controlled study of polytetraf luoroethylene versus saphenous vein in claudicant patients with bilateral above knee femoropopliteal bypasses. Surger y 1999;126:594-601
  10. Vossen RJ, Vahl AC, Fokkema TM, Leijdekkers VJ, van Swijndregt AM, Balm R. Endovascular therapy versus femoropopliteal bypass